John Mulligan, Bonum Therapeutics CEO

The crew that sold its lead IL-2 pro­gram to Roche is back with $93M to work on more next-gen I/O drugs

John Mul­li­gan was in the process of rais­ing about $90 mil­lion for a Se­ries B to take Good Ther­a­peu­tics’ PD-1-reg­u­lat­ed IL-2 in­to the clin­ic when …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.